Literature DB >> 21934600

Complete clinical and biological response to zoledronic acid in castrate-resistant prostate cancer metastatic to bone.

Damien Pouessel1, Stéphane Culine.   

Abstract

Zoledronic acid has been the standard of care for the prevention of skeletal-related events in patients with bone metastases from prostate cancer for the past 10 years. However, its potent antitumor activity has been questioned. We report the occurrence of a complete clinical and biological response to zoledronic acid in a patient with bone metastases from castrate-resistant prostate cancer.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 21934600     DOI： 10.1097/CAD.0b013e32834bede5

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN： 0959-4973            Impact factor:   2.248


  3 in total

1.  Inhibitory effects of CP on the growth of human gastric adenocarcinoma BGC-823 tumours in nude mice.

Authors:  Hai-Jun Wang; Yu Liu; Bao-Jun Zhou; Zhan-Xue Zhang; Ai-Ying Li; Ran An; Bin Yue; Li-Qiao Fan; Yong Li
Journal:  J Int Med Res       Date:  2018-03-23       Impact factor: 1.671

2.  Evaluation of safety and analgesic consumption in patients with advanced cancer treated with zoledronic acid.

Authors:  Andrej Kmetec; Tine Hajdinjak
Journal:  Radiol Oncol       Date:  2013-07-30       Impact factor: 2.991

Review 3.  The osteoblastic and osteoclastic interactions in spinal metastases secondary to prostate cancer.

Authors:  Sathana Dushyanthen; Davina A F Cossigny; Gerald M Y Quan
Journal:  Cancer Growth Metastasis       Date:  2013-11-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.